English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

DOI : 10.26650/IstanbulJPharm.2019.19004 Synthetic cannabinoid abuse becomes more common in recent years, although knowledge about the risk of the relatively new synthetic cannabinoid molecules is not adequate. Data is mainly limited with new analytical methods and case reports related to their clinical effects. The studies are generally related to the cardiac effects of first defined molecules rather than every molecule in the group. The cardiac clinical effects of synthetic cannabinoid abuse and underlying mechanisms are not certain. Therefore, we aimed to investigate AM-2201, one of synthetic cannabinoids, because knowledge for AM-2201 is less than the others in this group. The cardiotoxicity and underlying mechanisms of AM-2201 were assessed on cardiac cell culture. The half-maximal inhibition concentration (IC50) values were 101.49 and 63.33 M by WST-1 and LDH assays. AM-2201 was not induced either the total antioxidant capacity (TAC) or reactive oxygen species (ROS) levels. As to the measurements Annexin V-FITC and acridine orange dye, AM-2201 did not induce apoptosis and the primary cell death was necrosis. According to our results, further studies such as mechanism on cell death and cancer pathways should be investigated. You may cite this article as : Nisikli E, Celiksoz Akar M, Ozhan G (2019). The Assessment of in Vitro Cardiotoxic Potentials for Synthetic Cannabinoid, AM-2201. Istanbul J Pharm 10.26650/IstanbulJPharm.2019.19004.